Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole

• Status: Completed
• Trial end date: 2014-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Clopidogrel, an inhibitor of ADP induced platelet aggregation and activation, is one of the most commonly used drugs in patients with cardiovascular disease. The specific aim of the proposed study is to determine whether the interaction between proton-pump inhibitors (PPIs) and clopidogrel is dependent on CYP2C19 haplotype.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Neil Kleiman, MD
• Treatments: Clopidogrel; Omeprazole; Ticlopidine

Criteria

Inclusion Criteria:

• age 18- 65

• healthy - not taking any drugs / over the counter drugs regularly.

• ability and commitment to take the drugs and volunteer for 3 blood draws.

Exclusion Criteria:

• Taking any scheduled medication known to affect platelet function such as clopidogrel or NSAIDS11, COX2 inhibitors, beta blockers, calcium channel blockers, diuretics, anti-coagulants, older psychotropic agents, and recent ingestion of alcohol and caffeine

• Known history of heart disease

• Bleeding disorders

• Known allergy or contraindications to omeprazole or clopidogrel

• Pregnant and nursing women will also be excluded.